Results 71 to 80 of about 9,980,667 (237)

Establishment of two new predictive models for prostate cancer to determine whether to require prostate biopsy when the PSA level is in the diagnostic gray zone (4–10 ng ml−1)

Asian Journal of Andrology, 2020
Our goal was to establish two new predictive models of prostate cancer to determine whether to require a prostate biopsy when the prostate-specific antigen level is in the diagnostic gray zone. A retrospective analysis of 197 patients undergoing prostate
Jun Liu, Zhi-Qian Wang, Min Li, Ming-Yang Zhou, Yi-Fei Yu, Wei-Wei Zhan   +5 more
doaj   +1 more source

Intelligent Micro/Nanorobots for Targeted Interventional Therapy: From Bench to Clinic

Advanced Robotics Research, EarlyView.
Zirui Zhang et al. reviewed the application and challenges of mobile nanomachines in interventional therapy. By converting exogenous energy, including chemical, magnetic, optical, and ultrasonic sources, into mechanical forces, micro/nanorobots (MNRs) enable precise actuation at unprecedented scales. Evolving far beyond traditional drug delivery, these
Zirui Zhang, Yu Dong, Yongsheng Du, Rui Gao, Lin Zhang, Fei Tong   +5 more
wiley   +1 more source

Correlation of Total Serum Prostate Specific Antigen and Prostate Specific Antigen Density with subclinical inflammation in Benign Prostatic Hyperplasia

Journal of College of Medical Sciences-Nepal
Background Serum PSA is an important tumor marker for diagnosis of prostate cancer. However, it can rise in some other benign conditions like benign prostatic hyperplasia (BPH), prostatitis, prostatic infarct, instrumentation, prostate manipulations ...
Binita Goyal, Alina Baral
doaj   +1 more source

Single‐Cell Dissection of Therapy‐Induced Remodeling Uncovers a Fibroblast‐Driven Immunosuppressive Niche and Targetable Vulnerabilities in Lethal Prostate Cancer

Advanced Science, EarlyView.
Single‐cell longitudinal profiling reveals that androgen‐deprivation therapy induces a DPT+ fibroblast‐complement axis that suppresses macrophage inflammation and drives CD8+ T cell exhaustion in prostate cancer. Concurrently, resistant epithelial subpopulations persist and engage TSPAN1‐ and NRXN1‐mediated programs promoting CRPC and neuroendocrine ...
Yang Chen, Dandan Dong, Jinling Liao, Naikai Liao, Mengqi Liu, Qin Zhang, Siting Chen, Qi Liu, Ying Lu, Tianyu Li, Chunlin Zou, Qiong Song, Qiuyan Wang, Jian Liang, Qiji Xie, Chengyang Li, Mengyun Wang, Jiwen Cheng, Zengnan Mo, Gong‐Hong Wei   +19 more
wiley   +1 more source

Aptamer‐Engineered Liposomal Platform Enables in Situ cDC1 Vaccination to Potentiate Immunotherapy in Prostate Cancer

Advanced Science, EarlyView.
Prostate cancer is immunologically ‘cold’, with scarce, dysfunctional type 1 conventional dendritic cells (cDC1s) that limit T cell priming. We introduce an aptamer‐targeted liposomedelivering FMS‐like tyrosine kinase 3 ligand (Flt3L) and chlorin e6 (Ce6). Ultrasound induces antigen release and cDC1s recruitment, creating an in situ cDC1 vaccine.
Jiayi Wang, Xuan Wang, Xinfeng Dai, Linxin Tian, Wencheng Shen, Xueliang Liu, Wei Xue, Jiahua Pan, Yu Yang   +8 more
wiley   +1 more source

Metabolic syndrome as an independent determinant of prostate volume in elderly males over 60 years [PDF]

Journal of Men's Health
Background: There is a high incidence of metabolic syndrome (MS) and prostate disease in elderly males over 60 years old. This study aimed to investigate the influence of MS on prostate-specific antigen (PSA) levels, prostate volume (PV) and PSA ...
Yu Chen, Gansheng Xie, Yu Li
doaj   +1 more source

Toward Prostate Cancer Early Warning with a Self‐Powered Wearable Biosensing Platform Integrated with Machine Learning

Advanced Science, EarlyView.
ABSTRACT Current prostate cancer detection methods remain limited in non‐invasiveness and specificity, prompting interest in urinary biomarkers such as sarcosine. Here, we report a urine‐powered wearable platform for non‐invasive sarcosine detection as a proof‐of‐concept for decentralized early warning.
Jing Xu, Hanxiao Chen, Qichen Yuan, Liucun Yin, Yifang Tao, Hong Wang, Yuquan Xue, Delai Fu, Huan Pang, Tie Chong, Li Xue   +10 more
wiley   +1 more source

Prostate specific antigen expression does not necessarily correlate with prostate cancer cell growth

, 2006
PURPOSE: The antiproliferative effects of pharmacological agents used for androgen ablative therapy in prostate cancer, including goserelin, bicalutamide and cyproterone acetate (Fluka Chemie, Buchs, Switzerland), were tested in vitro.
Peternac, Daniel, Studer, Urs E, Klima, Irena, Cecchini, Marco G, Thalmann, George N   +4 more
core   +1 more source

Nomogram for predicting the probability of the positive outcome of prostate biopsies among Ghanaian men

African Journal of Urology, 2018
Introduction and objectives: Several existing models have been developed to predict positive prostate biopsy among men undergoing evaluation for prostate cancer (PCa). However, most of these models have come from industrialized countries.
F.A. Yeboah, E. Acheampong, C.K. Gyasi-Sarpong, K. Aboah, E.F. Laing, C. Obirikorang, B.T. Frimpong, G. Amoah, E.N. Batu, E.O. Anto, B. Amankwaah   +10 more
doaj   +1 more source

WT1‐Targeted Oral Bifidobacterium longum Vaccine Enhances Checkpoint Blockade Efficacy in Pancreatic Cancer

Advanced Science, EarlyView.
Oral WT1‐targeted Bifidobacterium longum vaccine promotes WT1‐associated cellular immunity and enhances anti‐PD‐1/anti‐CTLA‐4 efficacy in pancreatic cancer. ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains largely unresponsive to immune checkpoint inhibitors (ICI) due to its profoundly immunosuppressive tumor microenvironment.
Taiki Yamazaki, Aori Minami, Misako Hirota, Mirei Hirano, Ryota Sato, Atsuki Honma, Hideto Ueki, Toshiro Shirakawa   +7 more
wiley   +1 more source